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aPTT  are  often  normal  in  spite  of  therapeutic  dabigatran
plasma  levels.  Furthermore,  there  was  a  relatively  large
between—reagent  variability  in  the  response  to  dabigatran.
As  an  example,  when  the  aPTT  was  run  with  a  particu-
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Thrombosis Center, Department of Cliniclar  reagent,  35%  of  the  aPTT  ratios  were  in  the  normal
range  when  the  dabigatran  plasma  concentration  was  up
to  100  ng/mL.  Rodgers  et  al.  [9]  investigated  patients  on
rivaroxaban  and  found  that  the  recombinant  thromboplas-
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ptin  they  used  was  adequately  responsive  to  rivaroxaban.  O
the  contrary,  van  Veen  et  al.  [10],  while  investigating  the
patients  on  rivaroxaban  with  another  recombinant  throm
boplastin,  found  that  it  was  unresponsive  to  rivaroxaban
These  results  clearly  demonstrate  that  providing  presurg
cal  cut-off  values  without  taking  into  proper  consideratio
the  responsiveness  of  the  aPTT  or  PT  tests  to  dabigatra
or  rivaroxaban  may  create  a  dangerous  situation  for  patien
management.
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Dear  editor,
We  appreciate  the  pertinent  comment  from  Dr  Tripo
[1]  on  the  proposals  of  the  Working  Group  on  Perioperativ
Haemostasis,  regarding  management  of  major  bleeding  an
emergency  surgery  in  patients  on  long-term  treatment  wit
direct  anticoagulants  [2]. Several  clariﬁcations  need  to  b
made.
As  highlighted  by  Dr  Tripodi,  recommendations  can
not  be  established  because  of  the  lack  of  data  in  th
emergency  situation.  Therefore,  several  mundane  propo
sals  can  be  put  forward,  such  as:  ‘ideally,  surgery  must  b
delayed’;  but  how  many  times,  and  for  what  purpose?  
our  working  group,  we  decided  that  experts  must  develo
an  opinion  precisely  for  such  cases  where  there  is  no
clear  guidance.  Moreover,  we  addressed  the  proposals  for
DOIs of original articles:
http://dx.doi.org/10.1016/j.acvd.2014.04.003,
http://dx.doi.org/10.1016/j.acvd.2013.04.009.
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ergency  surgery  (i.e.  surgery  that  must  be  done  within
 hours)  that,  in  instances  such  as  peritonitis,  cannot  be
layed.
If  speciﬁc  dosages  are  available  for  an  anticoagulant
g,  we  ﬁxed  a  threshold  of  <  30  ng/mL  for  safe  emergency
gery.  We  agree  with  Dr  Tripodi  that  the  precise  thresh-
 is  unknown.  This  value  was  derived  from  (very  cautious)
armacokinetic  data,  alongside  data  in  guidelines  used
clinical  trials  for  elective  surgery  in  patients  receiving
se  anticoagulants.  The  modelling  of  this  dataset  led  us  to
ect  a  threshold  of  3  ng/mL,  but  we  accept  that  this  value
ains  theoretical.  However,  if  we  propose  use  of  such  a
eciﬁc  dosage  to  help  clinical  decision-making  in  the  case
surgery,  we  have  to  indicate  targets  for  concentrations  of
se  drugs.
In  France  —  but  we  cannot  assume  the  same  will  be
e  elsewhere  —  we  know  that  all  hospitals  in  charge  of
ergencies  do  not  dispose  24/24  of  such  dosages;  there-
e,  we  propose  an  alternative,  weaker  strategy,  based
 available  haemostatic  tests  (prothrombin  time  [PT]  and
tivated  partial  thromboplastin  time  [aPTT]),  effectively
th  a  high  level  of  uncertainty.  We  proposed  that  both
PT  and  an  aPTT  (and  not  PT  OR  aPTT,  as  suggested  by
 Tripodi)  can  be  taken  as  a  threshold  limit.  We  agree
t  this  proposal  has  severe  limitations,  but  again,  either
 hospitalized  teams  use  speciﬁc  tests  (which  is  actu-
y  not  possible  in  France,  from  a  cost  perspective),  or
 decide  to  manage  emergencies  without  having  per-
med  any  test  at  all.  Regardless,  as  discussed  in  our
blication,  we  agree  completely  with  Dr  Tripodi  that  all
oratories  must  analyse  the  accuracy  of  their  PT  and  aPTT347
asurements  for  determining  the  concentration  of  dabiga-
n  or  rivaroxaban.
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